Shawna Reigel, MD
Family Medicine · Moorestown, NJNPI 1619900586
Payments from drug & device makers
Across 256 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$658
- Novo Nordisk$518
- GSK$353
- Astellas Pharma US Inc$291
- Pfizer$287
- Mannkind Corporation$284
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,76397%
- Gifts$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $658 |
| Novo Nordisk | 38 | $518 |
| GSK | 26 | $353 |
| Astellas Pharma US Inc | 19 | $291 |
| Pfizer | 17 | $287 |
| Mannkind Corporation | 13 | $284 |
| AstraZeneca | 15 | $263 |
| Lilly USA, LLC | 12 | $195 |
| Amgen | 9 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $125 |
| Exact Sciences | 6 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Abbott | 5 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Boehringer Ingelheim | 5 | $64 |
| Amarin Pharma, Inc. | 3 | $42 |
| Valeritas, Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Novartis | 2 | $26 |
| Boston Scientific | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$3,882 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 37 | $34,608 |
| OzempicSemaglutide | 28 | $33,462 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $29,882 |
| MounjaroTirzepatide | 23 | $28,536 |
| XareltoRivaroxaban | 26 | $22,987 |
| EliquisApixaban | 25 | $22,123 |
| WegovySemaglutide | 15 | $19,762 |
| JanuviaSitagliptin Phosphate | 11 | $12,275 |
| JardianceEmpagliflozin | 14 | $11,773 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,899 |
| GemtesaVibegron | 11 | $5,380 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,496 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,022 |
| Atorvastatin Calcium | 239 | $2,927 |
| SynthroidLevothyroxine Sodium | 31 | $1,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $518 | $53,22443 claims |
| AstraZenecaFarxiga | $263 | $34,60837 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $353 | $32,90532 claims |
| Lilly USA, LLCMounjaro | $195 | $28,53623 claims |
| PfizerEliquis | $287 | $22,12325 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $64 | $17,67325 claims |
| MerckJanuvia | $12 | $12,27511 claims |
| AbbVieSynthroid | $658 | $1,79831 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $14 | $1,77112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Moorestown
- Sanjiv PatelMoorestown$14K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.